Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Responds to CMS Proposed Rule for CY 2022 PFS and Other Policy Changes (NCD 180.2)
-
Group Letter to Biden Administration Regarding Patent Eligibility Reform
-
ACMG Letter of Support for the Expanded Genetic Screening Act
-
ACMG Letter to Congress about Medicaid Coverage of Genetic and Genomic Testing
-
Group Sign-on Letter to Congress Expressing Concerns about Patent Eligibility Reform Stakeholder Discussions
-
ACMG Comments to CMS about Proposed Changes to the PFS for CY 2021
-
ACMG Letter to CMS Requesting Reconsideration of Payment Determination for a PALB2 CPT Code 81307
-
ACMG Comments to CMS Regarding CY 2020 CLFS Preliminary Payment Determinations
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act